Lasa Supergenerics to start pilot production trial run in Unit IV on November 25

Lasa Supergenerics Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 540702 | NSE: LASA

23 Nov 2017 Evaluate

Lasa Supergenerics will be commencing its pilot production trial runs in Unit IV effective from November 25, 2017. Products & capacity per annum will include Albendazole Intermediate 400 MT, Fenbendazole Intermediate 200MT, 2 4 DCP 600MT, Closantel Intermediate 100MT and additionally few components of backward integration for its recent new launches.

Lasa Supergenerics manufactures and distributes chemicals. The company offers veterinary API products, animal feed ingredients, and reagents for therapeutic uses.

Peers

Company Name	CMP
Sun Pharma. Inds.	1853.50
Dr. Reddys Labs.	1202.80
Cipla	1397.20
Lupin	2090.00
Zydus Lifesciences	1202.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.